Pharma Justifies Steep Prices, Plans Fancy Footwork In The Era Of Cures
Executive Summary
BioMarin CMO Geoff Nichol envisions "fancy footwork" in future payer negotiations for groundbreaking hemophilia therapy, during a discussion on value at the 2018 Biotech Showcase meeting, held in conjunction with the J.P. Morgan conference.
You may also be interested in...
Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
The First US Gene Therapy Maker Innovates On Pricing And Reimbursement
Spark priced the gene therapy Luxturna for inherited blindness at $850,000 for treatment of both eyes, below the $1m price some expected, and revealed pioneering market access plans. CEO Jeffrey Marrazzo and Harvard Pilgrim's Michael Sherman talked with Scrip about the details.
Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges
Levels of factor VIII in hemophilia A patients after treatment with new gene therapies are variable, a source of investor concern.